Galactose-based miR-122 targeting lipid calcium phosphate (Gal-LCP) nanoparticles were linked to elevated CD8+/CD4+ T cell ratios and decreased immunosuppressive cell infiltration, making the liver more receptive to antitumor immune responses, which may have successfully stopped colorectal cancer liver metastases and extended survival (50, 51). This evidence concerns the gene CD4 and colorectal cancer.